The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Zueva M.V.

FGBU "Moskovskiĭ NII glaznykh bolezneĭ im. Gel'mgol'tsa" Minzdravsotsrazvitiia Rossii

Saakian S.V.

Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russia

Electrophysiological evaluation of retinal function after systemic and superselective intra-arterial chemotherapy for retinoblastoma

Authors:

Zueva M.V., Saakian S.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2015;131(5): 111‑114

Read: 1624 times


To cite this article:

Zueva MV, Saakian SV. Electrophysiological evaluation of retinal function after systemic and superselective intra-arterial chemotherapy for retinoblastoma. Russian Annals of Ophthalmology. 2015;131(5):111‑114. (In Russ.)
https://doi.org/10.17116/oftalma20151315111-114

Recommended articles:
Electrophysiological methods in the diagnosis and moni­toring of glaucoma. Russian Annals of Ophthalmology. 2025;(4):102-109

References:

  1. Gobin YP, Dunkel IJ, Marr BP, Brodie SA, Abramson DH. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129(6):732-737. http://dx.doi.org/10.1001/archophthalmol.2011.5
  2. Abramson DH, Dunkel I, Brodie SE, Marr B, Gobin Y.P. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology. 2010;117(8):1623-1629. http://dx.doi.org/10.1016/j.ophtha.2009.12.030
  3. Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP. Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. Arch Ophthalmol. 2010;128(3):370-372. http://dx.doi.org/10.1001/archophthalmol.2010.7
  4. Abramson DH, Marr BP, Dunkel IJ Brodie S, Zabor EC, Driscoll SJ, Gobin YP. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding. Brit J Ophthalmol. 2012;96:499-502. http://dx.doi.org/10.1136/bjophthalmol-2011-300498
  5. Shields CL, Bianciotto CG, Jabbour P, Griffin GC, Ramasubramanian A, Rosenwasser R, Shielda JA. Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch Ophthalmol. 2011;129(11):1407-1415. http://dx.doi.org/10.1001/archophthalmol.2011.151
  6. Suzuki S, Yamane T, Mohri M, Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118(10):2081-2087. http://dx.doi.org/10.1016/j.ophtha.2011.03.013
  7. Harbour JW, Murray TG, Hamasaki D, Cicciarelli N, Hernández E, Smith B, Windle J, O’Brien JM. Local carboplatin therapy in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 1996;37:1892-1989. http://dx.doi.org/10.1001/archopht.1996.01100140585010
  8. Ripps H, Carr RE, Siegel IM, Greenstein VC. Functional abnormalities in vincristine-induced night blindness. Invest Ophthalmol Vis Sci. 1984;25:787-794. Available at: http://www.iovs.org/content/25/7/787.long. Accessed March 20, 2015.
  9. Francis JH, Rizzuti AE, Abramson DH. Chemotherapy for Retinoblastoma. Losing sight of visual outcome. Retinal Physician. 2009; Available at: http://www.retinalphysician.com/printarticle.aspx?articleID=103202. Accessed January 7, 2009.
  10. Rizzuti AE, Dunkel IJ, Abramson DH. The adverse events of chemotherapy for retinoblastoma: what are they? Do we know? Arch Ophthalmol. 2008;126:862-865. http://dx.doi.org/10.1001/archopht.126.6.862
  11. Shields CL, Shields JA, Needle M, de Potter P, Kheterpal S, Hamada A, Meadows AT. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology. 1997;104(12):2101-2111. http://dx.doi.org/10.1016/s0161-6420(97)30053-0
  12. Levy C, Doz F, Quintana E, Pacguement H, Michon J, Schlienger P, Validire P, Asselain B, Desjardins L, Zucker JM. Role of chemotherapy alone or in combination with hyperthermia in the primary treatment of intraocular retinoblastoma: preliminary results. Brit J Ophthalmol. 1998;82:1154-1158. http://dx.doi.org/10.1136/bjo.82.10.1154
  13. Bechrakis NE, Bornfeld N, Schueler A, Coupland SE, Henze G, Foerster MH. Clinicopathologic features of retinoblastoma after primary chemoreduction. Arch Ophthalmol. 1998;116:887-893. http://dx.doi.org/10.1001/archopht.116.7.887
  14. Demirci H, Shields CL, Meadows AT, Shields JA. Long-term visual outcome following chemoreduction for retinoblastoma. Arch Ophthalmol. 2005;123:1525-1530. http://dx.doi.org/10.1001/archopht.123.11.1525
  15. Desjardins L, Chefchaouni MC, Lumbroso L, Levy C, Asselain B, Bours D, Vedrenne J, Zucker JM, Doz F. Functional results after treatment of retinoblastoma. J AAPOS. 2002;6:108-111. http://dx.doi.org/10.1067/mpa.2002.121451
  16. Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Naduvilath TJ. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol. 2002;120:1653-1658. http://dx.doi.org/10.1001/archopht.120.12.1653
  17. Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology. 2007;114:162-169. http://dx.doi.org/10.1016/j.ophtha.2006.06.042
  18. Balasubramanya R, Pushker N, Bajaj MS, Rani A, Ghose S, Arya LS. Visual outcome in macular retinoblastoma treated with primary chemotherapy. Ophthalmologica. 2003;217:417-421. http://dx.doi.org/10.1159/000073072
  19. Ghose S, Nizamuddin SH, Sethi A, Mohanti KBK, Kumar H, Arya SLS, Thavaraj V. Efficacy of induction chemotherapy in retinoblastoma, alone or combined with other adjuvant modalities. J Pediatr Ophthalmol Strasbimus. 2002;39:143-150. http://dx.doi.org/10.1016/s0002-9394(02)01721-x
  20. Gobin YP, Dunkel IJ, Marr BP, Francis JH, Brodie SE, Abramson DH. Combined, Sequential Intravenous and Intra-Arterial Chemotherapy (Bridge Chemotherapy) for Young Infants with Retinoblastoma. PLoS ONE. 2012;7(9):e44322. http://dx.doi.org/10.1371/journal.pone.0044322
  21. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, Aerts I, Mercier G, Bours D, Desjardins L, Doz F. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral orbilateral retinoblastoma. Pediatr Blood Cancer. 2009;52(5):637-643. http://dx.doi.org/10.1002/pbc.21898
  22. McCulloch DL, Marmor MF, Brigell M, Hamilton R, Holder GE, Tzekov R, Bach M. ISCEV Standard for fuel-field clinical electroretinography (2015 update). Doc Ophthalmol. 2014;130(1):1-12. http://dx.doi.org/10.1007/s10633-014-9473-7
  23. Abramson DH, Dunkel I, Brodie SE Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115(8):1398-1404. http://dx.doi.org/10.1016/j.ophtha.2007.12.014
  24. Abramson DH. Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol. 2011;129(11):1492-1494. http://dx.doi.org/10.1001/archophthalmol.2011.354
  25. Brodie SE, Gobin YP, Marr BP, Dunkel I, Abramson DH. ERG Monitoring of retinal function after super-selective intra-arterial chemotherapy for retinoblastoma: 3-year results. ARVO 2010 Abstract 3277/A593. Available at: http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2511&sKey=ad008288-b817-4008-a3c9-3e55b4c78774&cKey=dfae0caa-e482-42f4-ae44-58136afdc2f7&mKey=1ea90e66-c548-49e0-9f05-30da7938d511. Accessed March 20, 2015.
  26. Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, Shields JA. The International classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276-2280. http://dx.doi.org/10.1016/s0084-392x(08)79145-7
  27. Brodie SE, Gobin PY, Dunkel LI, Kim JW, Abramson DH. Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol. 2009;119(1):13-22. http://dx.doi.org/10.1007/s10633-008-9164-3
  28. Brodie SE, Paulus YM, Patel M, Gobin YP, Dunkel IJ, Marr BP, Abramson DH. ERG monitoring of retinal function during systemic chemotherapy for retinoblastoma. Br J Ophthalmol. 2012;96(6):877-880. http://dx.doi.org/10.1136/bjophthalmol-2011-301248
  29. Munier FL, Beck-Popovic M, Balmer A, Galliard MC, Bovey E, Binardi S. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina. 2011;31(3):566-573. http://dx.doi.org/10.1007/s10633-008-9164-3
  30. Weiss AH, Kelly JP, Kapur RP, Pendergrass T. Retinal function and corresponding pathology in advanced retinoblastoma. Arch Ophthalmol. 2008;126:1507-1512. http://dx.doi.org/10.1001/archopht.126.11.1507
  31. Zueva M, Tsapenko I, Saakyan S, Panteleeva O, Zharua A, Orlovskaya L. [Functional state of the visual system in children with retinoblastoma, and its dynamics after superselective intraarterial chemotherapy]. Vestnik Oftal’mologii [Annals of Ophthalmology], 2014;(5):22-29. (In Russ.)

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.